About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-08-21
Henlius’ Serplulimab Prescribed for the First Time in Both Europe and India, Marking a Milestone Toward Global Accessibility
2025-08-19
Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
2025-08-14
Release of the Updated Abstract for Henlius’ PD-L1 ADC HLX43 at 2025 WCLC
2025-08-14
Ten studies on Henlius' innovative products to be showcased at WCLC 2025, Including Three Oral Presentations
2025-08-13
China NMPA Accepts New Drug Application for HLX04-O for Treatment of Ophthalmic Diseases
2025-08-07
Henlius to Initiate a Phase 1 Multicenter Study in US of Its PD-L1 ADC HLX43 for the Treatment of Thymic Carcinoma
2025-08-06
Henlius Doses First Patient in Phase 2 Trial of HLX79 and HANLIKANG for Glomerulonephritis
2025-07-31
First India Shipment of Henlius' Serplulimab
2025-07-28
CHMP Recommends EU Approval of Henlius’ Denosumab Biosimilar HLX14
1
2
3
...
8
